6o0k - Revision history

OCA at 07:02, 11 October 2023

OCA — Wed, 11 Oct 2023 07:02:41 GMT

←Older revision		Revision as of 07:02, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6o0k' size='340' side='right'caption='[[6o0k]], [[Resolution\|resolution]] 1.62Å' scene=''>		<StructureSection load='6o0k' size='340' side='right'caption='[[6o0k]], [[Resolution\|resolution]] 1.62Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6O0K FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6O0K FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-{4-[(4-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide'>LBM</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.62Å</td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BCL2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-{4-[(4-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl+)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide'>LBM</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [~~http~~://pdbe.org/6o0k PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [https://pdbe.org/6o0k PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [https://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.	+	[https://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN] Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).<ref>PMID:18570871</ref>	+	[https://www.uniprot.org/uniprot/B2CL1_HUMAN B2CL1_HUMAN] Potent inhibitor of cell death. Inhibits activation of caspases (By similarity). Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.<ref>PMID:19917720</ref> <ref>PMID:21840391</ref> Isoform Bcl-X(S) promotes apoptosis.<ref>PMID:19917720</ref> <ref>PMID:21840391</ref> [https://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN] Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).<ref>PMID:18570871</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 21:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 6o0k" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6o0k" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[B-cell lymphoma proteins 3D structures\|B-cell lymphoma proteins 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Birkinshaw~~, R W~~]]	+	[[Category: Birkinshaw RW]]
-	[[Category: Colman~~, P M~~]]	+	[[Category: Colman PM]]
-	[[Category: Czabotar~~, P E~~]]	+	[[Category: Czabotar PE]]
-	[[Category: Luo~~, C S]]~~	+	[[Category: Luo CS]]
-	~~[[Category: Apoptosis]]~~	+
-	~~[[Category: Bcl-2]]~~	+
-	~~[[Category: Complex]]~~	+
-	~~[[Category: Fda approved drug complex]]~~	+
-	~~[[Category: Protein-protein interface inhibitor]]~~	+
-	~~[[Category: Venetoclax~~]]	+

OCA at 17:39, 20 November 2019

OCA — Wed, 20 Nov 2019 17:39:37 GMT

←Older revision		Revision as of 17:39, 20 November 2019
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0K FirstGlance]. <br>		<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0K FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-[4-[~~[2-~~(4-~~chlorophenyl)~~-4,4-dimethyl-~~cyclohexen-~~1-yl]methyl]piperazin-1-yl]-~{N}-[4-(~~oxan~~-4-~~ylmethylamino)-3-~~[~~oxidanyl~~(~~oxidanylidene)~~-~~$l^{~~4}-~~azanyl~~]phenyl]sulfonyl-2-(~~1~{H}~~-pyrrolo[2,3-b]pyridin-5-~~yloxy~~)benzamide'>LBM</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-{4-[(4-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide'>LBM</scene></td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BCL2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BCL2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>

OCA at 06:29, 10 July 2019

OCA — Wed, 10 Jul 2019 06:29:35 GMT

←Older revision		Revision as of 06:29, 10 July 2019
Line 8:		Line 8:
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Note=A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/BCL2_HUMAN BCL2_HUMAN]] Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).<ref>PMID:18570871</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==

OCA at 06:35, 19 June 2019

OCA — Wed, 19 Jun 2019 06:35:32 GMT

←Older revision		Revision as of 06:35, 19 June 2019
Line 3:		Line 3:
	<StructureSection load='6o0k' size='340' side='right'caption='[[6o0k]], [[Resolution\|resolution]] 1.62Å' scene=''>		<StructureSection load='6o0k' size='340' side='right'caption='[[6o0k]], [[Resolution\|resolution]] 1.62Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0K FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0K FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-~{N}-[4-(oxan-4-ylmethylamino)-3-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide'>LBM</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-~{N}-[4-(oxan-4-ylmethylamino)-3-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide'>LBM</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BCL2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>
	</table>		</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing therapy. To understand the molecular basis of this acquired resistance we describe the crystal structures of venetoclax bound to both BCL-2 and the G101V mutant. The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. The G101V mutant complex structure and mutant binding assays reveal that resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation. This provides a framework for considering analogues of venetoclax that might be effective in combating this mutation.
		+
		+	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.,Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1. PMID:31160589<ref>PMID:31160589</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6o0k" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Birkinshaw, R W]]		[[Category: Birkinshaw, R W]]

OCA at 06:53, 23 May 2019

OCA — Thu, 23 May 2019 06:53:54 GMT

←Older revision		Revision as of 06:53, 23 May 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6o0k ~~is ON HOLD until Paper Publication~~	+	==crystal structure of BCL-2 with venetoclax==
-		+	<StructureSection load='6o0k' size='340' side='right'caption='[[6o0k]], [[Resolution\|resolution]] 1.62Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6o0k]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0K OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0K FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2PE:NONAETHYLENE+GLYCOL'>2PE</scene>, <scene name='pdbligand=LBM:4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-~{N}-[4-(oxan-4-ylmethylamino)-3-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide'>LBM</scene></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0k OCA], [http://pdbe.org/6o0k PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0k RCSB], [http://www.ebi.ac.uk/pdbsum/6o0k PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0k ProSAT]</span></td></tr>
		+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Birkinshaw, R W]]
		+	[[Category: Colman, P M]]
		+	[[Category: Czabotar, P E]]
		+	[[Category: Luo, C S]]
		+	[[Category: Apoptosis]]
		+	[[Category: Bcl-2]]
		+	[[Category: Complex]]
		+	[[Category: Fda approved drug complex]]
		+	[[Category: Protein-protein interface inhibitor]]
		+	[[Category: Venetoclax]]

OCA at 05:43, 21 May 2019

OCA — Tue, 21 May 2019 05:43:51 GMT

←Older revision		Revision as of 05:43, 21 May 2019
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6o0k is ON HOLD	+	The entry 6o0k is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6o0k" [edit=sysop:move=sysop]

OCA — Wed, 27 Feb 2019 13:46:37 GMT

Protected "6o0k" [edit=sysop:move=sysop]

←Older revision

Revision as of 13:46, 27 February 2019

OCA: New page: '''Unreleased structure''' The entry 6o0k is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 27 Feb 2019 13:46:35 GMT

New page: '''Unreleased structure''' The entry 6o0k is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6o0k is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]